Publicacions
-
Gorostegui M, Muñoz JP, Pérez-Jaume S, Simao-Rafael M, Cristina Larrosa Espinosa, Garraus-Oneca M, Salvador-Marcos N, Lavarino C, Krauel L, Mañe S, Castañeda-Heredia A and Mora J.
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 Immunotherapy
Cancers . 16(9): . Nº de cites: 1
-
Muñoz JP, Cristina Larrosa Espinosa, Chamorro S, Pérez-Jaume S, Simao M, Sanchez-Sierra N, Varo A, Gorostegui M, Castañeda-Heredia A, Garraus-Oneca M, Lopez-Miralles S and Mora J.
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
Cancers . 15(19): . Nº de cites: 7
-
Mora J, Castañeda-Heredia A, Gorostegui M, Varo A, Pérez-Jaume S, Simao M, Muñoz JP, Garraus-Oneca M, Cristina Larrosa Espinosa, Salvador-Marcos N, Lavarino C, Krauel L and Mañe S.
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report
Cancers . 15(9): . Nº de cites: 8
-
Torner-Rubies F, Nuñez JH, Inarejos E, Garraus-Oneca M, Suñol M, Deyà-Martinez A and Moreno-Romo D.
Total calcaneal allograft reconstruction of an Ewing's sarcoma in a child: Outcome and review of the literature
CANCER REPORTS . 5(9): . Nº de cites: 2
-
Castañeda-Heredia A, Gorostegui M, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J.
How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Deu in Barcelona, Spain
ESMO Open . 7(2): 100462-100462. Nº de cites: 10
-
Inarejos E, Navarro OM, Navallas M, Enrique Ladera Gonzalez, Torner-Rubies F, Suñol M, Garraus-Oneca M, March JC and Barber-Martínez de la Torre I.
Multiparametric MRI evaluation of bone sarcomas in children
Insights into Imaging . 13(1): 33-33. Nº de cites: 7
-
Mora J, Castañeda-Heredia A, Gorostegui M, Santa-María V, Garraus-Oneca M, Muñoz JP, Varo A, Pérez-Jaume S and Mañe S.
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission
PEDIATRIC BLOOD & CANCER . 68(10): 29121. Nº de cites: 21
-
Castillo H, Pascual-Pastó G, Pérez-Jaume S, Resa-Parés C, Vilà-Ubach M, Monterrubio C, Jimenez-Cabaco A, Baulenas-Farrés M, Muñoz-Aznar O, Salvador-Marcos N, Cuadrado-Vilanova M, Gene-Olaciregui N, Balaguer-Lluna L, Burgeño-Sandoval V, Vicario FJ, Manzanares-Quintela A, Castañeda-Heredia A, Santa-María López V, Cruz-Martínez O, Celis-Passini V, Morales-La Madrid A, Garraus-Oneca M, Gorostegui M, Vancells M, Carrasco-Torrents R, Krauel L, Torner-Rubies F, Suñol M, Lavarino C, Mora J and Carcaboso AM.
Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas
JOURNAL OF PATHOLOGY CLINICAL RESEARCH . 7(4): 338-349. Nº de cites: 15
-
Mora J, Castañeda-Heredia A, Colombo MC, Gorostegui M, Fernando Gómez Muñoz, Mañe S, Santa-María López V, Garraus-Oneca M, Macias N, Pérez-Jaume S, Muñoz-Aznar O, Muñoz JP, Barber-Martínez de la Torre I and Suñol M.
Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma
Cancers . 13(6): 164. Nº de cites: 7
-
Mora J, Castañeda-Heredia A, Flores MA, Santa-María V, Garraus-Oneca M, Gorostegui M, Simao M, Pérez-Jaume S and Mañe S.
The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies
FRONTIERS IN PHARMACOLOGY . 11: 575009-575009. Nº de cites: 15